talquetamab
janssen
['multiple myeloma', 'talquetamab']
70% of heavily pretreated patients taking #talquetamab for multiple myeloma see responses that deepen over time #ash22 via 
Evidence-Based #Oncology. Bringing together perspectives of 20,000+ cancer care #providers, #payers, #policymakers, #patients, and researchers in #cancer care.